FEAF
TWSE

9945 潤泰新

28.35 ▲ 0.70 (2.53%) Close · 2026-11-13 · TWSE
Ask about 9945
This is research, not a buy or sell recommendation. Robo-advice in Taiwan requires an FSC licence; FEAF analyses, explains and monitors, and the investor makes the decision. Judgement thresholds are working rules pending review by the team's finance members.

Plain-language summary of valuation, growth, profitability, balance sheet, and recent MOPS filings.

Your risk profile
Conclusion

Overall picture is positive: 5 strengths and no major watch-outs in the data reviewed.

For a moderate profile, none of the items above crosses the watch-out thresholds set by the team.

No model narrative: the model call failed. The structured analysis above is complete on its own.

Strengths

+ The current price implies -1.0% perpetual growth, within the 3.5% ceiling: expectations look attainable. source (Valuation) →
+ P/E 4.59 is well below the Other median of 12.09 (42 listed peers): priced cheaper than peers. source (Key Stats) →
+ Revenue grew 23.6% in 2025; latest quarter Q3 2026: 8.7% year on year. source (Financials) →
+ Liabilities are only 31.3% of total assets (Q3 2026): a light debt load. source (Financials) →
+ Free cash flow was positive in 2025: 4,590 NT$ million. source (Financials) →

Watch-outs

——

What the analysis found

+ Valuation (DCF) The current price implies -1.0% perpetual growth, within the 3.5% ceiling: expectations look attainable. source →
+ Valuation vs peers P/E 4.59 is well below the Other median of 12.09 (42 listed peers): priced cheaper than peers. source →
+ Growth Revenue grew 23.6% in 2025; latest quarter Q3 2026: 8.7% year on year. source →
· Profitability Return on equity 9.5% with a 37.4% net margin: moderate profitability. source →
+ Debt Liabilities are only 31.3% of total assets (Q3 2026): a light debt load. source →
+ Cash flow Free cash flow was positive in 2025: 4,590 NT$ million. source →
· Filings 1 verified alert(s); latest on 2026-11-12: 公告本公司董事會決議通過115年第3季合併財務報告 source →
· Filings 2 filing(s) are held or rejected and wait for human review. source →